Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
JAZZ PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS, LLC
Case Number:
2:13-cv-00391
Court:
Nature of Suit:
Judge:
Firms
- Carella Byrne
- Duane Morris
- Fox Rothschild
- Lerner David
- Quinn Emanuel
- Saiber LLC
- Saul Ewing
- Walsh Pizzi
Companies
- Amneal Pharmaceuticals Inc.
- Jazz Pharmaceuticals Inc.
- Lupin Ltd.
- Par Pharmaceutical Cos. Inc.
- Ranbaxy
- Sun Pharmaceutical Industries Ltd.
- Wockhardt Bio AG
- Wockhardt Ltd.
- Wockhardt USA LLC
Sectors & Industries:
-
May 13, 2016
Jazz Makes Deal In Xyrem IP Fight With Ranbaxy, Sun, Ohm
Jazz Pharmaceuticals Inc. has agreed to drop its claims against generic-drug makers Ranbaxy, Sun and Ohm in a patent infringement case involving the narcolepsy drug Xyrem after the companies resolved their differences and struck a licensing agreement, the company told a New Jersey federal judge Thursday.
-
January 22, 2016
Judge Threatens 'Severe' Sanctions In Xyrem IP Fight
A New Jersey federal magistrate judge concluded Friday that generic drugmakers Par Pharmaceutical Inc. and Amneal Pharmaceutical LLC "unequivocally" violated a court order when their attorneys made reference to confidential inter partes review documents during related patent litigation over the narcolepsy drug Xyrem.
-
January 15, 2016
Jazz's Xyrem Patent Cases Consolidated In NJ Fed Court
A New Jersey federal judge has ordered the consolidation of several infringement cases brought by Jazz Pharmaceuticals against other drug companies regarding its patents for Xyrem, a narcolepsy drug the company has attempted to block generic manufacturers from producing for years.
-
June 25, 2014
Drug Challenged Under AIA Biz Method Review For 1st Time
Amneal Pharmaceuticals LLC and others asked the Patent Trial and Appeal Board on Tuesday to invalidate a patent for distribution of Jazz Pharmaceuticals Inc.'s narcolepsy drug Xyrem as an abstract idea, the first time the America Invents Act's business method review program has been used in a drug case.